N4 Pharma Plc., United Kingdom
As a trained immunologist and virologist, Melody Sauerborn entered the fascinating world of biologics during her PhD. She focused on investigating why biologics induce the formation of anti-drug antibodies. After obtaining her PhD, Dr. Sauerborn established herself in the areas of bioanalysis and immunogenicity by spending numerous years in CROs and biotech companies. She worked predominantly on developing and validating ligand-binding and cell-based assays for PK/Tox and immunogenicity studies for biologics, biosimilars and vaccines. During her role as the head of non-clinical development at Mymetics, a viral vaccine company, she also extended and added to her expertise the production of biologics, vaccines and ATMPs and the aspects of potency assays and GMP. Currently Dr. Sauerborn focuses as a freelance on projects including (non-) clinical immunogenicity assessment, PK/PD assays, production of vaccines and biologics and teaching bioanalytical method validation workshops across Europe (and sometimes beyond).